Lun, 12 de febrero de 2024
Swissmedic’s latest approvals spotlight oncology with ten new cancer drugs leading the charge. This landmark development reinforces Switzerland’s commitment to advancing healthcare and therapeutic innovation.
Swissmedic, Switzerland’s authority in therapeutic products, has recently sanctioned 41 medicines featuring novel active ingredients. Oncology emerges as the primary field, with ten new drugs receiving approval, highlighting the significant focus on cancer treatment advancements. Additionally, Swissmedic authorized four new medications in hematology, showcasing a commitment to enhancing treatment options in this vital area.
The announcement on Monday also highlighted approvals in other critical sectors, including vaccines, diagnostics, endocrinology, metabolism, and rheumatology. The distribution across these sectors remains consistent with the previous year’s trends, underscoring Swissmedic’s balanced approach to healthcare innovation.
In 2023, Swissmedic evaluated 49 medicines with new active substances, approving an impressive 84%. The remaining 16% saw withdrawal of their applications by the companies involved. Beyond new medicines, Swissmedic reviewed 79 applications for extending existing medicinal products’ applications, approving 82% of these requests.
This robust approval rate reflects Swissmedic’s dedication to expanding and enhancing therapeutic options for patients across Switzerland, further positioning the country at the forefront of medical and therapeutic innovation.
©Keystone/SDA
Spanish 
English 
German 
French 
Arabic